Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 8, Number 10—October 2002
THEME ISSUE
Bioterrorism-related Anthrax

Bioterrorism-related Anthrax

Public Health in the Time of Bioterrorism

Bradley A. Perkins*, Tanja Popovic*, and Kevin Yeskey*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

On Thursday, October 4, 2001, just 24 days after the tragic events of September 11, the Florida Department of Health and the Centers for Disease Control and Prevention (CDC) confirmed the first case of inhalational anthrax in the United States in more than 25 years. Recognition of this unexpected case is attributed to the alertness of local infectious disease physician Larry Bush, who promptly notified Jean Malecki, director, Palm Beach County Health Department (1,2). By Saturday, October 6, a team of federal, state, and local public health and local law enforcement investigators identified intentional Bacillus anthracis spore contamination at the patient’s workplace. These events marked the beginning of the first U.S. outbreak of bioterrorism-related anthrax and (for many of us in clinical medicine, public health, and law enforcement) ushered in the transition from tabletop bioterrorism exercises to real-world investigation and response.

Contingency plans to mitigate bioterrorism-related anthrax outbreaks go back to August 1998, when CDC hosted the “Workshop on Improving Public Health Response to Possible Acts of Bioterrorism.” This workshop brought together state and local health departments, public health professional organizations, the U.S. Department of Defense, and the U.S. Department of Justice to examine ways of improving public health preparedness for bioterrorism (CDC, unpub. data). Two investments made as a result of this workshop were the Laboratory Response Network for Bioterrorism and the National Pharmaceutical Stockpile. These early investments were key components of the public health response to the 2001 bioterrorism-related anthrax outbreak.

The Laboratory Response Network was created at the recommendation of the 1998 Workshop’s “Diagnosis Working Group,” the then Association of State and Territorial Public Health Laboratories (now Association for Public Health Laboratories), and CDC. The Laboratory Response Network is a tiered system of laboratories with capacities defined in an A (lowest tier) through D (highest) pyramid structure (3,4). In support of this structure, procedures for identification of B. anthracis, and other Category A biologic agents, were validated, and in some instances developed (or redeveloped) de novo on the basis of older methods. Protocols were written into standard laboratory procedure manuals. Reagents for testing were standardized, produced, and distributed by CDC to participating laboratories. State health department laboratory scientists were trained to use these methods for identifying B. anthracis, Yersinia pestis (causative agent of plague), and Francisella tularensis (causative agent of tularemia) in the fall and winter of 2000. Capacity for specialized or more developmental diagnostic and other tests for B. anthracis (e.g., real time polymerase chain reaction [PCR] [5], direct fluorescent-antibody assay [6], immunohistochemical testing, molecular subtyping [7], and antimicrobial susceptibility testing [8]) were established at CDC and (in some instances) at a small number of other advanced U.S. laboratories (e.g., U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland; Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona). For serologic testing, which was found to be invaluable in identifying anthrax cases during the investigation, existing tests developed for vaccine evaluation were adapted for diagnostic purposes (9). All these laboratory measures were in place before the 2001 anthrax outbreak.

During the acute phase of the outbreak, Laboratory Response Network laboratories processed >121,700 specimens for B. anthracis (the bulk from environmental specimens from areas of suspected or confirmed contamination). Public Health Laboratories (other than CDC) tested 84,000 (69%) specimens; the Department of Defense tested 30,200 (25%) specimens; and CDC tested 7,500 (6%) (CDC, unpub. data). Handling the unusual surge of demand without the support of the Laboratory Response Network is difficult to imagine and would have likely compromised the investigation.

The National Pharmaceutical Stockpile was another investment made as a result of the 1998 Workshop and put in place before the 2001 outbreak. During the outbreak, the pharmaceutical stockpile team transported not only antibiotics, anthrax vaccine, clinical and environmental samples, and B. anthracis isolates but also epidemiologists, laboratory scientists, pathologists, and specialized teams of researchers. Under extreme pressure, the team made 143 sorties to 9 states and delivered 3.75 million antibiotic tablets from October 8, 2001 to January 11, 2002 (CDC, NPS Program Logistics Log, Oct 2001–Jan 2002).

Other earlier public health investments that paid off during the anthrax outbreak investigation were CDC’s more than 50-year-old applied epidemiology training program, Epidemic Intelligence Service, and other academic, state and local health department, and CDC efforts to develop the seasoned cadre of field epidemiologists (10,11) that make up the core of public health investigation and response. These epidemiologists, who work in established networks and make up and often lead complex partnerships, comprise the public health front lines of the bioterrorism response team.

The complexity of the 2001 anthrax investigation and response challenged even experienced field epidemiologists. At the state and federal levels, “incident command”-style management structures were used to address the constant emergence of new information, pursue many public health activities simultaneously across multiple investigations, and communicate effectively. These management structures, which have been adopted by the disaster management and law enforcement communities, are less familiar to public health workers. With some variation from site to site, a typical field investigation structure included local, state, and federal public health partners working on the following teams: Epidemiologic Investigation (what happened?), Intervention (post-exposure prophylaxis and follow-up), Surveillance (identify additional cases), Clinical Evaluation (rapidly evaluate suspect cases), Environmental Assessment (environmental sampling and processing), Remediation (working with the Environmental Protection Agency), and Communication (with the public, partners, and press). These teams were sometimes complemented with Federal Bureau of Investigation (FBI) liaisons; in some cases, public health officials were assigned to FBI investigation teams (12). A senior epidemiologist was also posted to FBI Headquarters in Washington, D.C.

After the October 12 recognition of cutaneous anthrax in New York (13), an emergency operations center was established at CDC, Atlanta, Georgia, to coordinate the outbreak investigation and response. The center tasked more than 2,000 employees (in the field or at headquarters in Atlanta) (CDC unpub. data) to specific functions, including 24-hour response capacity with telephone information and call-triage services and other specialized teams (14). CDC/Atlanta-based teams led by senior epidemiologists supported each field investigation team in involved jurisdictions (Florida, New York, Washington D.C., New Jersey, and Connecticut). These teams were in direct and frequent communication with their respective field team about laboratory results, other investigations, and policy decisions. Other teams included the following: Clinical Medicine (evaluation of suspected cases, post-exposure prophylaxis and treatment recommendations) (1521); Environmental Assessment (evaluation of suspected or confirmed areas of environmental contamination); International Support (22,23); Laboratory Support (coordination across CDC laboratories and the Laboratory Response Network); National Pharmaceutical Stockpile (antibiotics, vaccine, specimens, and people transport); Postal Service Liaison (partnership with the U.S. Postal Service—CDC also assigned a senior epidemiologist to the Postal Service); and State Liaison (to coordinate requests from states without confirmed anthrax cases) (24). Beginning on October 12, CDC’s Morbidity and Mortality Weekly Report published a series of reports, notices, and guidelines as events unfolded (25).

Many unknowns confronted the public-health response team during the anthrax investigation (26). The basics about exposure to B. anthracis–contaminated envelopes specifically sent to media outlets and government leaders were understood quickly, given the events in Florida, New York, and then Washington, D.C. (13). Difficulties arose in characterizing anthrax risk to individuals and groups with suspected or confirmed exposure to B. anthracis–contaminated envelopes or environments (27). Challenges also arose in the evaluation of B. anthracis-containing powders, epidemiologic investigation (28), environmental assessment (29,30) and remediation, surveillance (31,32), diagnosis, treatment, and post-exposure prophylaxis (3335).

Work with B. anthracis–contaminated goat hair in textile mills more than 40 years ago provided some data about the risk of B. anthracis spore-containing particles in naturally contaminated occupational environments. These data suggested that relatively high levels of B. anthracis spores were “not necessarily or consistently dangerous” in this setting (36). Biologic warfare experts considered it unlikely that terrorists could produce a B. anthracis spore powder for use in an envelope that would be capable of generating substantial primary (or secondary) aerosol threats for human infection or widespread contamination of environments. Yet, in Senator Daschle’s office, in the Hart Senate Office building, in the room where the letter was opened (as well as outside the room) exposed persons’ nasal mucosa were almost immediately contaminated (37). Re-aerosolization (secondary aerosol) at a level consistent with potential transmission was demonstrated off the implicated high-speed sorter in the Brentwood Processing and Distribution Facility (38). Recent research using simulates of B. anthracis spores from the Canadian Defense Establishment Suffield suggests that contaminated envelopes can cause heavy aerosol contamination (39). New understanding is accumulating, and this should improve public health response in the future.

The decision-making involved in closing the U.S. Postal Service’s Brentwood Processing and Distribution Facility, Washington, D.C., has been criticized. The risk to Brentwood facility employees by contaminated envelopes in transit was not recognized in time to prevent illness in four employees, two of whom died (40). Decisions concerning the Brentwood facility were based on epidemiologic observations in Florida and New York, where no disease occurred among postal workers. A possible explanation for the differential risk is that the B. anthracis spore preparation in the October 9 envelopes had a higher potential for aerosolization than the preparation in the September 18 envelopes or that the two mailings were made under or exposed to different environmental conditions (e.g., amount of moisture) that created a different potential for aerosolization. A different aerosolization potential is supported by the epidemic curve in the manuscript by Jernigan et al. (13), which shows a higher proportion of inhalational (versus cutaneous) anthrax cases associated with the October 9 mailing. In naturally occurring disease, once risk is understood, it generally remains constant; however, in intentional contamination, risk may be altered by the perpetrator(s).

During the anthrax investigation, the public health response team was better prepared in some areas than in others. Five deaths were not prevented, but widespread illness and death was averted through early recognition of threats and prompt intervention. We applied what we knew and learned what we did not know. We gained new appreciation for communication and partnerships. For the first time, on November 8, 2001, a sitting President of the United States of America, George W. Bush, visited CDC to support the efforts of public health professionals and others who participated in the anthrax investigation and response. Leaders and individual heroes rose in the ranks of public health, clinical medicine, and law enforcement (41). The substantial role of public health in the 2001 anthrax investigation and response suggests that strong public health infrastructure supported by applied public health and basic-science research are key elements to the control and prevention of future bioterrorism threats.

Acknowledgment

The guest editors of this special issue of Emerging Infectious Diseases thank all colleagues who participated in the 2001 bioterrorism investigation and response and all who contributed to articles in this issue.

References

  1. Traeger MS, Wiersma S, Rosenstein NE, Malecki JM, Shepard CW, Raghunathan P, First case of bioterrorism-related inhalational anthrax in the United States□Palm Beach County, Florida 2001. Emerg Infect Dis. 2002;8:102934.PubMed
  2. Maillard J-M, Cline S, Turner L, Fischer M. First case of bioterrorism-related inhalational anthrax, Florida, 2001: North Carolina investigation. Emerg Infect Dis. 2002;8:10358.PubMed
  3. Centers for Disease Control and Prevention. Biological and chemical terrorism: strategic plan for preparedness and response. MMWR Morb Mortal Wkly Rep. 2000;49:126.PubMed
  4. Khan AS, Morse S, Lillibridge S. Public-health preparedness for biologic terrorism in the USA. Lancet. 2000;356:117982. DOIPubMed
  5. Hoffmaster AR, Meyer RF, Bowen M, Marston CK, Weyant RS, Barnett GA, Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. Emerg Infect Dis. 2002;8:117882.PubMed
  6. De BK, Bragg SL, Sanden GN, Wilson KE, Diem LA, Marston CK, A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthraci. Emerg Infect Dis. 2002;8:10605.PubMed
  7. Hoffmaster AR, Fitzgerald CC, Ribot E, Mayer LW, Popovic T. Molecular subtyping of Bacillus anthracis and the 2001 bioterrorism-related anthrax outbreak, United States. Emerg Infect Dis. 2002;8:11116.PubMed
  8. Mohammed MJ, Marston CK, Popovic T, Weyant RS, Tenover FC. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol. 2002;40:19027. DOIPubMed
  9. Quinn CP, Semenova VA, Elie CM, Romero-Steiner S, Greene C, Li H, Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis. 2002;8:11038.PubMed
  10. Thacker SB, Dannenberg AL, Hamilton DH. Epidemic intelligence service of the Centers for Disease Control and Prevention: 50 years of training and service in applied epidemiology. Am J Epidemiol. 2001;154:98592. DOIPubMed
  11. Bales ME, Dannenberg AL, Brachman PS, Kaufmann AF, Klatsky PC, Ashford DA. Epidemiologic response to anthrax outbreaks: field investigations, 1950−2001. Emerg Infect Dis. 2002;8:116374.PubMed
  12. Butler J, Cohen M. Collaboration between public health and law enforcement: new paradigms and partnerships for bioterrorism planning and response. Emerg Infect Dis. 2002;8:11526.PubMed
  13. Jernigan D, Raghunathan P, Ashford D, Bell B, Brechner R, Bresnitz E, Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:101928.PubMed
  14. Mott JA, Treadwell T, Hennessy T, Rosenberg P, Wolfe M, Brown C, Call-tracking data and the public health response to bioterrorism-related anthrax. Emerg Infect Dis. 2002;8:108892.PubMed
  15. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:93344.PubMed
  16. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:90919.PubMed
  17. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:9418.PubMed
  18. Centers for Disease Control and Prevention. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep. 2001;50:960.PubMed
  19. Centers for Disease Control and Prevention. Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:10146.PubMed
  20. Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8:2225.PubMed
  21. Barakat LA, Quentzel HL, Jernigan JA, Kirschke DL, Griffith K, Spear SM, Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002;287:863□8.
  22. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax, 2001. MMWR Morb Mortal Wkly Rep. 2001;50:100810.PubMed
  23. Polyak CS, Macy JT, Irizarry-De La Cruz M, Lai JE, McAuliffe J, Popovic T, Bioterrorism-related anthrax: international response by the Centers for Disease Control and Prevention activities. Emerg Infect Dis. 2002;8:10569.PubMed
  24. Tengelsen L, Hahn C, Hudson R, Barnes S. Coordinated response to possible anthrax contamination, Idaho, 2001. Emerg Infect Dis. 2002;8:10935.PubMed
  25. Centers for Disease Control and Prevention. Selected articles. Special issue. MMWR Morb Mortal Wkly Rep 2001; 50:877;889–897;909–919;941–948;960;961;962;973–976;984–986;987–990;991;1008–1010;1014–1016;1049–1051;1051–1054..
  26. Perkins BA, Ashford D. Bioterrorism-related Bacillus anthracis public health research priorities (meeting summary). Emerg Infect Dis. 2002;8:1183.
  27. Centers for Disease Control and Prevention. Interim guidelines for investigation and response to Bacillus anthracis exposures. MMWR Morb Mortal Wkly Rep 2001;50:987□90.
  28. Greene C, Reefhuis J, Tan C, Fiore AE, Goldstein S, Beach M, Epidemiologic investigations of bioterrorism-related anthrax, New Jersey, 2001. Emerg Infect Dis. 2002;8:104855.PubMed
  29. Sanderson WT, Hein M, Taylor L, Curwin B, Kinnes G, Seitz T, Surface sampling methods for Bacillus anthracis spore contamination. Emerg Infect Dis. 2002;8:114551.PubMed
  30. Teshale EH, Painter J, Burr GA, Wright SV, Cseh LF, Zabrocki R, Environmental sampling for spores of Bacillus anthracis. Emerg Infect Dis. 2002;8:10877.
  31. Tan CG, Sandhu H, Crawford D, Redd S, Beach M, Buehler J, Surveillance for anthrax cases associated with contaminated letters□New Jersey, Delaware, and Pennsylvania, 2001. Emerg Infect Dis. 2002;8:10737.PubMed
  32. Williams A, Parashar U, Stoica A, Ridzon R, Kirschke D, Meyer R, Bioterrorism-related anthrax surveillance in Connecticut, September□December, 2001. Emerg Infect Dis. 2002;8:107882.PubMed
  33. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:112432.PubMed
  34. Jefferds MD, Laserson K, Fry AM, Roy S, Hayslett J, Grummer-Strawn L, Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis. 2002;8:113844.PubMed
  35. Williams JL, Noviello SS, Griffith KS, Wurtzel H, Hamborsky J, Perz JF, Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001. Emerg Infect Dis. 2002;8:113347.PubMed
  36. Brachman PS, Plotkin SA, Bumford FH, Atchison MM. An epidemic of inhalation anthrax: the first in the twentieth century. Am J Hyg. 1960;72:623.PubMed
  37. Hsu VP, Lukacs SL, Handzel T, Hayslett J, Harper S, Hales T, Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. Emerg Infect Dis. 2002;8:103943.PubMed
  38. Dull P, Wilson K, Kournikakis B, Boulet C, Ho J, Ogston J, Bacillus anthracis aerosolization associated with a contaminated mail sorting machine. Emerg Infect Dis. 2002;8:10447.PubMed
  39. Kournakakis B., Armour SJ, Boulet CA, Spence M, Barsons B. Risk assessment of anthrax threat letters. DRES Technical Report TR 2001-048. September, 2001.
  40. Dewan PK, Fry AM, Laserson K, Tierney BC, Quinn CP, Hayslett JA, Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis. 2002;8:106672.PubMed
  41. Gerberding JL, Hughes JM, Koplan JP. Bioterrorism preparedness and response: clinicians and public health agencies as essential partners. JAMA. 2002;287:898900. DOIPubMed

Figures

DOI: 10.3201/eid0810.020444

Table of Contents – Volume 8, Number 10—October 2002

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

TOP